Cargando…

A circulating miR-19b-based model in diagnosis of human breast cancer

Abstract Objective: Breast cancer (BC) is becoming the leading cause of cancer-related death in women all over the word. Identification of diagnostic biomarkers for early detection of BC is one of the most effective ways to reduce the mortality. Methods: Plasma samples from BC patients (n = 120) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Qian, Shen, Lei, Lü, Jinhui, Xie, Heying, Li, Danni, Shang, Yuanyuan, Huang, Liqun, Meng, Lingyu, An, Xuefeng, Zhou, Jieru, Han, Jing, Yu, Zuoren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523242/
https://www.ncbi.nlm.nih.gov/pubmed/36188229
http://dx.doi.org/10.3389/fmolb.2022.980841
_version_ 1784800232068874240
author Zhao, Qian
Shen, Lei
Lü, Jinhui
Xie, Heying
Li, Danni
Shang, Yuanyuan
Huang, Liqun
Meng, Lingyu
An, Xuefeng
Zhou, Jieru
Han, Jing
Yu, Zuoren
author_facet Zhao, Qian
Shen, Lei
Lü, Jinhui
Xie, Heying
Li, Danni
Shang, Yuanyuan
Huang, Liqun
Meng, Lingyu
An, Xuefeng
Zhou, Jieru
Han, Jing
Yu, Zuoren
author_sort Zhao, Qian
collection PubMed
description Abstract Objective: Breast cancer (BC) is becoming the leading cause of cancer-related death in women all over the word. Identification of diagnostic biomarkers for early detection of BC is one of the most effective ways to reduce the mortality. Methods: Plasma samples from BC patients (n = 120) and normal controls (n = 50) were collected to determine the differentially expressed circulating miRNAs in BC patients. Binary logistic regression was applied to develop miRNA diagnostic models. Receiver operating characteristic (ROC) curves were applied to calculate the area under the curve (AUC). MMTV-PYMT mammary tumor mice were used to validate the expression change of those circulating miRNAs. Plasma samples from patients with other tumor types were collected to determine the specificity of the model in diagnosis of BC. Results: In the screening phase, 5 circulating miRNAs (miR-16, miR-17, miR-19b, miR-27a, and miR-106a) were identified as the most significantly upregulated miRNAs in plasma of BC patients. In consistence, the 5 miRNAs showed upregulation in the circulation of additional 80 BC patients in a tumor stage-dependent manner. Application of a tumor-burden mice model further confirmed upregulation of the 5 miRNAs in circulation. Based on these data, five models with diagnostic potential of BC were developed. Among the 5 miRNAs, miR-19b ranked at the top position with the highest specificity and the biggest contribution. In combination with miR-16 and miR-106a, a miR-19b-based 3-circulating miRNA model was selected as the best for further validation. Taken the samples together, the model showed 92% of sensitivity and 90% of specificity in diagnosis of BC. In addition, three other tumor types including prostate cancer, thyroid cancer and colorectal cancer further verified the specificity of the BC diagnostic model. Conclusion: The current study developed a miR-19b-based 3-miRNA model holding potential for diagnosis of BC using blood samples.
format Online
Article
Text
id pubmed-9523242
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95232422022-10-01 A circulating miR-19b-based model in diagnosis of human breast cancer Zhao, Qian Shen, Lei Lü, Jinhui Xie, Heying Li, Danni Shang, Yuanyuan Huang, Liqun Meng, Lingyu An, Xuefeng Zhou, Jieru Han, Jing Yu, Zuoren Front Mol Biosci Molecular Biosciences Abstract Objective: Breast cancer (BC) is becoming the leading cause of cancer-related death in women all over the word. Identification of diagnostic biomarkers for early detection of BC is one of the most effective ways to reduce the mortality. Methods: Plasma samples from BC patients (n = 120) and normal controls (n = 50) were collected to determine the differentially expressed circulating miRNAs in BC patients. Binary logistic regression was applied to develop miRNA diagnostic models. Receiver operating characteristic (ROC) curves were applied to calculate the area under the curve (AUC). MMTV-PYMT mammary tumor mice were used to validate the expression change of those circulating miRNAs. Plasma samples from patients with other tumor types were collected to determine the specificity of the model in diagnosis of BC. Results: In the screening phase, 5 circulating miRNAs (miR-16, miR-17, miR-19b, miR-27a, and miR-106a) were identified as the most significantly upregulated miRNAs in plasma of BC patients. In consistence, the 5 miRNAs showed upregulation in the circulation of additional 80 BC patients in a tumor stage-dependent manner. Application of a tumor-burden mice model further confirmed upregulation of the 5 miRNAs in circulation. Based on these data, five models with diagnostic potential of BC were developed. Among the 5 miRNAs, miR-19b ranked at the top position with the highest specificity and the biggest contribution. In combination with miR-16 and miR-106a, a miR-19b-based 3-circulating miRNA model was selected as the best for further validation. Taken the samples together, the model showed 92% of sensitivity and 90% of specificity in diagnosis of BC. In addition, three other tumor types including prostate cancer, thyroid cancer and colorectal cancer further verified the specificity of the BC diagnostic model. Conclusion: The current study developed a miR-19b-based 3-miRNA model holding potential for diagnosis of BC using blood samples. Frontiers Media S.A. 2022-09-16 /pmc/articles/PMC9523242/ /pubmed/36188229 http://dx.doi.org/10.3389/fmolb.2022.980841 Text en Copyright © 2022 Zhao, Shen, Lü, Xie, Li, Shang, Huang, Meng, An, Zhou, Han and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Zhao, Qian
Shen, Lei
Lü, Jinhui
Xie, Heying
Li, Danni
Shang, Yuanyuan
Huang, Liqun
Meng, Lingyu
An, Xuefeng
Zhou, Jieru
Han, Jing
Yu, Zuoren
A circulating miR-19b-based model in diagnosis of human breast cancer
title A circulating miR-19b-based model in diagnosis of human breast cancer
title_full A circulating miR-19b-based model in diagnosis of human breast cancer
title_fullStr A circulating miR-19b-based model in diagnosis of human breast cancer
title_full_unstemmed A circulating miR-19b-based model in diagnosis of human breast cancer
title_short A circulating miR-19b-based model in diagnosis of human breast cancer
title_sort circulating mir-19b-based model in diagnosis of human breast cancer
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523242/
https://www.ncbi.nlm.nih.gov/pubmed/36188229
http://dx.doi.org/10.3389/fmolb.2022.980841
work_keys_str_mv AT zhaoqian acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT shenlei acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT lujinhui acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT xieheying acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT lidanni acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT shangyuanyuan acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT huangliqun acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT menglingyu acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT anxuefeng acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT zhoujieru acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT hanjing acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT yuzuoren acirculatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT zhaoqian circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT shenlei circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT lujinhui circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT xieheying circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT lidanni circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT shangyuanyuan circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT huangliqun circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT menglingyu circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT anxuefeng circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT zhoujieru circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT hanjing circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer
AT yuzuoren circulatingmir19bbasedmodelindiagnosisofhumanbreastcancer